Cayman Islands counsel to Structure Therapeutics Inc., a clinical-stage global biopharmaceutical company, in relation to its August 2025 shelf-registration statement and at-the-market offering of up to US$250 million. Lucy Anderson led our team.
Cayman Islands counsel to Structure Therapeutics Inc., a clinical-stage global biopharmaceutical company, in relation to its August 2025 shelf-registration statement and at-the-market offering of up to US$250 million. Lucy Anderson led our team.